Abstract
Background: Privileged structures are potentially able to bind to a diverse range of biologically important proteins with high affinities, thus benefiting the discovery of novel bioactive compounds. 1,2-Benxisoxazole derivatives can be such important types of “privileged structures” possessing a rich diversity of biological properties especially in the area of CNS disorders. Methods: This review seeks to explore the most significant examples of 1,2-benzisoxazoles as privileged structures in terms of polypharmacology at the molecular level, specifically focusing on four 1,2-benzisoxazoles (zonisamide, risperidone, paliperidone, and iloperidone) which have been in clinical use and established as effective therapeutics. Furthermore, an updated and detailed account of the pharmacological properties of 1,2-benzisoxazole derivatives as therapeutics for CNS disorders is described. And finally, outlooks on current issues and future directions in this field are also provided. Results: 1,2-Benzisoxazole was successfully employed in the discovery and development of zonisamide for the treatment of epilepsy and Parkinson’s disease. 1,2- Benzisoxazole is also a significantly important structure for the development of atypical antipsychotics. Conclusion: It is very reasonable to say that 1,2-benzisoxazole is a good example of a privileged structure because it forms the centerpiece of small molecule chemical entities with a wide range of pharmacological properties, especially in the area of CNS disorders.
Keywords: 1, 2-benzisoxazole, privileged structures, polypharmacology, antipsychotics, antiepileptics, Parkinson’s disease.
Current Pharmaceutical Design
Title:1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Volume: 22 Issue: 21
Author(s): Yoshikazu Uto
Affiliation:
Keywords: 1, 2-benzisoxazole, privileged structures, polypharmacology, antipsychotics, antiepileptics, Parkinson’s disease.
Abstract: Background: Privileged structures are potentially able to bind to a diverse range of biologically important proteins with high affinities, thus benefiting the discovery of novel bioactive compounds. 1,2-Benxisoxazole derivatives can be such important types of “privileged structures” possessing a rich diversity of biological properties especially in the area of CNS disorders. Methods: This review seeks to explore the most significant examples of 1,2-benzisoxazoles as privileged structures in terms of polypharmacology at the molecular level, specifically focusing on four 1,2-benzisoxazoles (zonisamide, risperidone, paliperidone, and iloperidone) which have been in clinical use and established as effective therapeutics. Furthermore, an updated and detailed account of the pharmacological properties of 1,2-benzisoxazole derivatives as therapeutics for CNS disorders is described. And finally, outlooks on current issues and future directions in this field are also provided. Results: 1,2-Benzisoxazole was successfully employed in the discovery and development of zonisamide for the treatment of epilepsy and Parkinson’s disease. 1,2- Benzisoxazole is also a significantly important structure for the development of atypical antipsychotics. Conclusion: It is very reasonable to say that 1,2-benzisoxazole is a good example of a privileged structure because it forms the centerpiece of small molecule chemical entities with a wide range of pharmacological properties, especially in the area of CNS disorders.
Export Options
About this article
Cite this article as:
Uto Yoshikazu, 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology, Current Pharmaceutical Design 2016; 22 (21) . https://dx.doi.org/10.2174/1381612822666160224142648
DOI https://dx.doi.org/10.2174/1381612822666160224142648 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extensive Coronary Calcification: A Clinically Unrecognised Condition
Current Vascular Pharmacology Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia
Mini-Reviews in Medicinal Chemistry Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors
Current HIV Research Rapid Analysis and Separation of Stilbenes
Current Analytical Chemistry Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Vascular Risk Factors and Lesions of Vascular Nature in Magnetic Resonance as Predictors of Progression to Dementia in Patients with Mild Cognitive Impairment
Current Alzheimer Research Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Rapid Screening of Antioxidant Active Constituents from Puerariae Lobatae Radix Based on the Investigation of Quantitative Patteren-Activity Relationship
Current Analytical Chemistry Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Pharmaceutical Design Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
Current Drug Safety Marine Products with Anti-Protozoal Activity: A Review
Current Clinical Pharmacology Thrombophilia in Pregnancy: Maternal and Fetal Implications
Current Women`s Health Reviews Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Leptin and Vascular Smooth Muscle Cells
Current Pharmaceutical Design Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: The Medicinal Chemistry of New Agents to Treat Obesity (Guest Editor: Jinhwa Lee)]
Current Topics in Medicinal Chemistry The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidative Stress in Atherosclerosis Development: The Central Role of LDL and Oxidative Burst
Endocrine, Metabolic & Immune Disorders - Drug Targets